Short answer
Kura Oncology, Inc. (KURA) filed an 8-K current report with the SEC on June 4, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers), Item 5.07 (Submission of Matters to a Vote of Security Holders). Shareholders approved 6,500,000 additional common shares for employee equity awards under the Amended 2014 Plan.
Kura Oncology, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.02 · Departure/Election of Directors or Officers
- Shareholders approved 6,500,000 additional common shares for employee equity awards under the Amended 2014 Plan
- Shareholders approved 2,500,000 additional common shares under the Employee Stock Purchase Plan
- Expanded share authorization supports employee retention and incentive programs
- Potential future dilution for existing shareholders from increased equity issuance capacity
Item 5.07 · Submission of Matters to a Vote of Security Holders
- 69,778,580 shares represented, covering 78.6% of 88,762,704 outstanding shares
- All three Class III director nominees elected through 2029, with Michael Vasconcelles receiving strongest support
- Ernst & Young ratified for fiscal 2026, reducing near-term auditor-governance uncertainty
- Say-on-pay approved; annual executive-compensation votes selected with 48,362,762 votes
- Amended equity plan and ESPP approved, preserving employee incentive and stock-purchase capacity
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Kura Oncology, Inc. 8-K filings
Get the next KURA 8-K as it lands
Follow KURA for push alerts, or ask the research agent what this filing means.